INTRODUCTION

Alopecia areata has a variable course and uncertain natural history. All patients of alopecia areata may not require treatment. Spontaneous regrowth in some cases with limited disease process is well known.\(^1\)\(^2\) Although diverse therapeutic options are available, none of them is satisfactory. Moreover, it is not yet identifiable as to which patient of alopecia areata will progress into extensive disease or alopecia totalis/ universalis and will require intervention. In these patients too, the ideal and effective treatment protocol is yet to be evolved.

How to cite this article: Khaitan BK, Mittal R, Verma KK. Extensive alopecia areata treated with betamethasone oral mini-pulse therapy: An open uncontrolled study. Indian J Dermatol Venereol Leprol 2004;70:350-3.

uncontrolled study design.

METHODS

Sixteen patients, 11 males and 5 females, between 14-36 years in age (median age 26 years) with severe alopecia areata attending the outpatient department of All India Institute of Medical Sciences, New Delhi were taken for the study. The duration of the disease at the time of presentation ranged from 1 month to 11 years (mean 3 years 2 months). The diagnosis in each patient was made on the basis of history and clinical presentation. Five patients had previously received various modalities of treatment including corticosteroids (systemic daily dose, topical or intralesional), minoxidil and herbal treatment with variable results, while the remaining patients were untreated. However, none of these patients were on any treatment for at least 3 months at the time of their inclusion in the study. There was no history of alopecia areata in the family. Neither was there personal or family history of atopy in any of the patients. All patients were thoroughly evaluated clinically.

The baseline investigations included complete hemogram, blood sugar, serum electrolytes, renal and liver function tests, chest X-ray, urinalysis and examination of stool especially for occult blood. All the patients underwent an ophthalmologic evaluation before starting the therapy. Blood pressure and body weight were recorded initially and monitored every month.

All the patients were treated with oral mini-pulse (OMP) therapy comprising of betamethasone 5 mg given as a single oral dose after breakfast on two consecutive days every week. The patients were treated with this regime for a minimum period of 6 months and then OMP was tapered step-wise every month once cosmetically acceptable regrowth was achieved. The eyebrows and eyelashes began to respond in 1-4 months (mean 2 months). Hair growth over the extremities started in about 3-4 months.

At the end of 6 months, 7 patients (43.7%) showed an excellent response (Figure 1-2) after which the dose of betamethasone was tapered step-wise and finally stopped. In the subsequent follow-up (5 to 8 months) there was a relapse in 1 patient after 2 months of stoppage of treatment and OMP had to be restarted. Another patient showed scanty re-growth of hair on the eyebrows. Five (31.2%) patients showed a good response after 6 months of therapy (Figure 3-4). Betamethasone was continued in these patients in the same doses (5 mg) for another 2 months and then gradually tapered and finally stopped. There has been no relapse in this group of patients. Two (12.5%) patients showed an unsatisfactory response at the end of 6 months. The dosage was tapered in next two months

<table>
<thead>
<tr>
<th>Type</th>
<th>No. of cases</th>
<th>Excellent</th>
<th>Good</th>
<th>Unsatisfactory</th>
<th>No response</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alopecia universalis</td>
<td>9</td>
<td>3</td>
<td>3</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Alopecia totalis</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Extensive alopecia areata (&gt;50% of scalp involvement)</td>
<td>6</td>
<td>4</td>
<td>1</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Total</td>
<td>16</td>
<td>7</td>
<td>5</td>
<td>2</td>
<td>2</td>
</tr>
</tbody>
</table>
to 3 mg of betamethasone and was continued till one year and then tapered off in the next 3 months. Further improvement was not significant. The remaining two (12.5%) patients were non-responders and both had alopecia universalis. In one of them there was growth of a few vellus hair.

The best response was seen on the scalp. The extremities and eyebrows still showed a few remaining areas of hair loss and required further topical treatment with corticosteroids with variable response. The side effects noted were cushingoid facies and weight gain in 2 patients and acneiform eruption in 2 patients. Three patients complained of mild gastric discomfort which responded to antacids and H₂ blockers. At present there are 12 patients who are off treatment since 5 to 8 months and there has been no relapse.

DISCUSSION

The available treatment modalities for alopecia areata can be divided into:²,³
(a) Non-specific irritants - dithranol, phenol
(b) Immune inhibitors - systemic corticosteroids, PUVA
(c) Immune enhancers or universal contact allergens – dinitrochlorobenzene (DNB), diphencrypropane (DPC) and diphenylcyclopropenone (DPCP).
(d) Miscellaneous agents with uncertain mechanism of action and effect – minoxidil.
The efficacy of systemic corticosteroids as a therapeutic modality for severe alopecia areata is observed by various workers but the justification of its use remains debatable. It restores normal hair growth in majority of the cases but most cases have shown relapse at some stage during or after withdrawal of treatment. Pasricha et al treated a single patient with 5 mg of betamethasone twice weekly with a rapid re-growth of hair all over the scalp in 3 months. Sharma administered oral prednisolone as pulses in doses of 300 mg at 4 weeks intervals. Cosmetically acceptable hair growth was seen in 58.3% patients at 4 months of treatment and relapse was seen in 2 patients after stoppage of therapy at 3 and 9 months respectively. In another study, Sharma et al have reported complete hair growth in 26.6% of patients and a good response in 36.6% of patients treated with oral mini-pulse with dexamethasone. In our study, cosmetically acceptable hair growth was seen at a mean of 5 months of therapy. There had been relapse in one patient 4 months after stoppage of treatment who had subsequently been re-started on the same regimen and at present there are 12 out of 16 patients who are off treatment since 5 to 8 months without any relapse.

As per the guidelines of care for alopecia areata after treating a patient with extensive disease for 2-6 months, if no response is seen, another therapy may be tried. Daily oral corticosteroids have high efficacy, however their long-term use may result in serious side effects. To avoid these side effects, pulse therapy was conceived. Dexamethasone-cyclophosphamide pulse therapy in pemphigus patients has been widely accepted. Its chief aim is to provide maximum efficacy with minimal side-effects. With similar intentions, we used OMP with betamethasone in our patients of alopecia areata with equally good results and lesser side effects. OMP may be used for longer periods with minimal side effects as compared to daily doses of corticosteroids. Even if a relapse occurs, the therapy may be repeated and thus remission may be achieved in a larger proportion of cases.

In our study the response was good to excellent in 12 (75%) patients and unsatisfactory or nil in 4 (25%) patients. We therefore conclude that betamethasone oral mini-pulse therapy is a convenient and fairly effective treatment modality for extensive alopecia areata. However, randomized controlled trials with standard therapies on a larger number of patients are required to give more insight into the efficacy and safety of oral mini-pulse therapy for extensive alopecia areata.

REFERENCES